After todays TBI secondary indication announcement, we are now chasing a $4B TAM - triples our upside, diversifies our downside
And with @jellyroll 's research into the IXC patent for Glaucoma and our board members OPT CEO Megan Baldwin, I think I have just clocked what IXC management are doing:
- Run a Phase III for IIH with a strong Mechanism of Action that translates across many indications with raised ICP.
- Acquire a portfolio of multiple secondary indications IP to magnify the upside of M&A Exit value
- Not invest a further dollar regarding R&D for these secondary indications, but own the exclusive Orphan rights to sell GLP-1RAs for them for 10 years.
- Sell post Phase III to a major pharma company for a few B's (hundreds of millions more than what they could if it was only IIH).
I am a big fan of this approach; best maximisation of shareholder value, lowest cost (No need for CR) and shortest time to exit.
Congratulations to the team.
- Forums
- ASX - By Stock
- IXC
- Ann: Invex Granted European Orphan Drug Designation for TBI
Ann: Invex Granted European Orphan Drug Designation for TBI, page-16
-
-
- There are more pages in this discussion • 59 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IXC (ASX) to my watchlist
|
|||||
Last
6.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.960M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 6.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.8¢ | 10000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 0.062 |
1 | 15500 | 0.061 |
1 | 150000 | 0.060 |
1 | 100000 | 0.052 |
1 | 60001 | 0.041 |
Price($) | Vol. | No. |
---|---|---|
0.068 | 10000 | 1 |
0.069 | 16500 | 1 |
0.070 | 40000 | 1 |
0.076 | 888 | 1 |
0.083 | 4000 | 1 |
Last trade - 16.12pm 12/07/2024 (20 minute delay) ? |
Featured News
IXC (ASX) Chart |
Day chart unavailable